The phytosteroid ecdysterone was recently reported to enhance performance in sports and may thus be considered as a substance of relevance in anti-doping control. To trace back an administration of ecdysterone from urine samples analytical properties have been investigated to assess its integration into initial testing procedures (ITP) in doping control laboratories.
Introduction
Ecdysterone (chemical structure in Figure 1 ) is widely marketed as a "natural anabolic agent", advertised to increase strength and muscle mass during resistance training, to reduce fatigue and to ease recovery. Growth promoting and anabolic effects in various animal species including humans have been reported [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Ecdysterone appeared to promote an anabolic effect that was reported to be even stronger than that of the anabolic androgenic steroid (AAS) metandienone [19, 20] . Contrary to the effect of AASs, it appears that the effect of ecdysterone is mediated by an activation of estrogen receptor beta (ERbeta) [1, [21] [22] [23] . A few studies reported a performance enhancing effect in animals, but only recently a controlled administration trial in humans showed significant performance enhancement in resistance training [24] . Thus, the administration of ecdysterone may be considered as a practice that leads to an unfair advantage in sports competitions and may therefore be considered as doping. Indeed, ecdysterone was already suspected to be used by Olympic athletes since the 1980s and was also called a "Russian secret" [11, 19, 20, [24] [25] [26] .
The administration of prohibited substances in sports is generally traced back from the analysis of biological specimen. The majority of substances is covered by the analysis of urine samples from athletes utilizing mass spectrometric detection hyphenated to chromatographic separation [27, 28] . Sample preparation often includes cleavage of potential phase-II metabolites, concentration of the analytes using liquid-liquid (LLE) or solid phase extraction (SPE). For GC-MS analysis derivatization of the analytes to their TMS-derivatives is most frequently performed for less volatile compounds [28] [29] [30] .
A few studies report the metabolism of ecdysterone, however most of them do not refer to humans [3, [31] [32] [33] [34] . As stated by Lafont et al. [31] considerable differences between species have been observed and thus, transferability is questionable. In humans, desoxy-ecdysterone was reported as urinary metabolite, however structure assignment differed between the two studies. While Brandt [34] reported 14-desoxy-ecdysterone, a 2-desoxy metabolite was described in Tsitsimpikou et al. [33] .
Herein we investigate the analytical properties of ecdysterone and evaluate different alternatives to trace back its administration from the analysis of doping control samples using GC-or LC-MS based methods.
Materials and methods

Chemicals and reagents
Reference substances of the phytosteroids ecdysterone (2β,3β,14α,20β,22R,25-hexahydroxy-5β-cholest-7-en-6-one, parent compound, PC) and ecdysone (2β,3β,14α,22R,25pentahydroxy-5β-cholest-7-en-6-one, 1) were purchased from Steraloids (Newport, USA), while ponasterone (2β,3β,14α,20β,22R-pentahydroxy-5β-cholest-7-en-6-one, 2) was obtained from Cayman Chemical Company (Ann Arbor, Michigan USA). Methyltestosterone (used as internal standard for urine analysis) was obtained from Sigma Aldrich (Milano, Italy).
The preparation of β-glucuronidase from Escherichia coli was from Roche Diagnostic (Mannheim, Germany). The derivatizing agent (TMIS reagent) was a mixture of N-methyl-N- Polisher and a 0.22-μm membrane point-of-use cartridge (Millipak).
Synthesis of 14-desoxy-ecdysterone (3)
Desoxygenation of ecdysterone was performed as described by Kumpun et al. [3] . A solution of 200 mg of ecdysterone in 2.4 mL of acetic acid was treated with 250 mg of zinc powder while stirring for 24 h at 70°C. After filtration an aliquot was diluted with water and analyzed by LC-QTOF-MS. Three desoxy-ecdysterone isomers were detected with the two major assigned according to Kumpun et al. and Zhu et al. [3, 35] to the 14α-H (most abundant, earlier eluting, 3) and 14β-H product (second most abundant, later eluting, 3b).
Urine samples
Post administration urines were collected following the administration of 51.5 mg of ecdysterone (checked for identity and purity) to one healthy volunteer. All samples (as they accrued) were collected for 33 hours, followed by spot urines of the following three days. All samples were anonymized and handled in accordance with the ethical standards of the Helsinki Declaration. Informed consent form was signed by the volunteer. Samples were stored in aliquots at -18°C and gently thawed at +4°C for sample preparation.
Instrumentation
Analyses were performed evaluating different instruments, i.e. GC-QTOF-MS, LC-QTOF-MS and LC-QQQ-MS. Mass Hunter B10 software from Agilent Technologies Inc. (Santa Clara, CA, USA) and Analyst Version 1.6.2 (AB Sciex, Monza, Italy) software were used for data acquisition and processing.
LC-QTOF-MS
LC-HRMS was performed on an Agilent 6550 Q-TOF mass spectrometer coupled to an Agilent 1290 II UHPLC equipped with an Agilent Eclipse Plus C18 column (2.1 mm x 100 mm, particle size 1.8 μm). A linear gradient (starting at 5% B and increasing to 25% at 7 min, then to 95% at 13 min, 3 min hold, followed by 2 min re-equilibration at 5% B) was used with water 
LC-QQQ-MS
The LC-MS/MS instrument comprised of an Agilent 1200 with binary gradient system (Agilent Technologies S.p.A, Cernusco sul Naviglio, Milano, Italy) coupled to an API 4000 triple quadrupole mass spectrometer (ABSciex, Monza, Italy). Ionization was performed by ESI in positive mode, using a curtain gas pressure of 25 psi, a source temperature of 550 °C, an ion source gas 1 pressure of 35 psi, an ion source gas 2 pressure of 40 psi, a declustering voltage of 80 V, an entrance potential of 10 V and a needle voltage of 5500 V. The experiments were performed using multiple reaction monitoring (MRM) as acquisition mode, employing collisioninduced dissociation (CID) using nitrogen as collision gas at 5.8 mPa, obtained from a dedicated nitrogen generator system Parker-Balston model 75-A74, gas purity 99.5% (CPS analitica Milano, Italy). The ion transitions selected for ecdysterone were: 481→371 (CE=28 eV), 481→445 (CE=25 eV), and 481→165 (CE=35 eV), whereas for ecdysone and ponasterone the selected ion transitions were 465→447 (CE=25 eV), 465→429 (CE=27 eV) and 465→285 (CE=27 eV).
The RP-HPLC separation was adopted from the method currently used in the World Anti-Doping Agency (WADA) accredited anti-doping laboratory of Rome [36] using a Supelco discovery C18 column (2.1 x 150mm, 5 μm) with a mobile phase of water containing formic acid (1000:1, v:v, eluent A) and acetonitrile and formic acid (1000:1, v:v, eluent B). The gradient program starts at 10% of eluent B and increases to 60% of eluent B in 3 min, 6 min hold, then to 90% of eluent B in 2 min, 1 min hold, followed by 4 min re-equilibration at 10% of eluent B.
The flow rate was set at 250 µL/min and the column was maintained at ambient temperature.
Aliquots of 10 µL were injected using an Agilent 1200 autosampler.
GC-QTOF-MS
GC-QTOF-MS was performed as regularly done in the Anti-Doping Laboratory in Rome. An Agilent 7200 GC-QTOF-MS (Waldbronn, Germany) coupled by electron ionization (EI, 70 eV at 250 °C) to an Agilent 7890B GC was equipped with an HP1 Ultra1 capillary column (length 17 m, 0.2 mm i.d., 0.11 µm film thickness). Helium was used as carrier gas (1 mL/min, constant flow) and the oven temperature was programmed at 188 °C (2.5 min hold), was increased at 3 °C/min to 211 °C (2 min hold), at 10 °C/min to 238 °C, at 40 °C/min to 320 °C (hold 3.2 min).
An aliquot of 2 µL was injected in split mode (1:20) . Improved separation used a modified temperature program, however, evaluation was intended to use the routinely performed separation of the laboratory to meet initial testing procedures.
Reference solutions or the final extracts of sample preparation were evaporated and derivatized using 100 µL of TMIS reagent.
Evaluation of pre-analytical sample processing
Extraction procedures
To evaluate the possibilities of extraction and concentration of the analytes, ecdysterone parent compound was used as model substance. For solid phase extraction different cartridges (HLB Oasis HLB and WCX, both Waters, Milan, Italy, as well as Chromabond C18, C18 Hydra, and HR-X, all Macherey-Nagel, Düren Germany), were tested. After conditioning, cartridges were loaded with 2 mL of urine spiked with ecdysterone. After washing elution was performed with 1 mL of methanol (either with or without addition of formic acid or ammonium formate).
The eluate was evaporated and reconstituted in 50 µL of purified water to yield the injection solution for LC-MS analysis.
Additionally, liquid-liquid extraction was evaluated at different pH values and using different extraction solvents. Aliquots of 2 mL of blank urine spiked with ecdysterone were adjusted to pH 5, 7 or 9 and extracted with 5 mL of solvent (TBME, ethyl acetate, chloroform, or a mixture of chloroform with isopropanol). Analyses were performed by LC-MS/MS.
Recoveries were determined by comparison with a reference solution spiked into urine after the extraction.
Application to post administration samples
For LC-MS analysis urine samples were spiked with the internal standard methyltestosterone, diluted with water (1:4, v:v) and injected into the system after centrifugation at 800 g.
Alternatively, GC-QTOF analysis was performed after extraction and derivatization using a mixture of MSTFA:NH 4I:DTE (1000:2:4, v/w/w, TMIS reagent) within 2 h at 75 °C.
For evaluation of a potential cleavage of phase-II metabolites enzymatic hydrolysis with βglucuronidase or a mixture of β-glucuronidase and arylsulfatase was performed before the analysis.
To 2 mL of each urine sample adjusted to pH 7 by addition of 1.5 mL of phosphate buffer, 50 µL of internal standard solution (methyltestosterone, 200 ng/mL) and 50 µL of βglucuronidase from Escherichia coli (Roche Diagnostics, Mannheim, Germany) were added.
Deglucuronidation was performed within 1 hour at 50 °C.
Additionally cleavage of potential glucuronides and sulfates was performed while incubating 2 mL of urine, adjusted to pH 5.2, with 50 µL of β-glucuronidase arylsulfatase mix after addition of the internal standard (methyltestosterone). Incubation was carried out for 3 h at 50°C.
Results and discussion
Mass spectrometry
The mass spectrometric properties of ecdysterone and the two other ecdysteroids ecdysone and ponasterone (both desoxy analogues of ecdysterone accessible as reference materials) as well as the synthesized 14-desoxy-ecdysterone were analyzed by GC-MS and LC-MS.
Derivatization, that was required for GC-MS analyses, was performed using TMIS reagent that Similar fragments were reported by Brandt [34] , however, in unit mass resolution. The retention times of the above mentioned reference steroids in LC-QTOF-MS are listed in Table 1 .
Extraction procedure
Ecdysterone is known as a relatively polar steroid (logP = -0.53, according to ACDLabs prediction and reported at www.scifinder.cas.org). Ecdysone and ponasterone show slightly less polarity (logPecdysone = 0.875, logPponasterone = 1.434), thus still even more polar compared to cortisol (logPcortisol = 1.762, for comparison logPtestosterone = 3.179). Extraction was therefore evaluated using TBME that is utilized in lots of extraction procedures in anti-doping laboratories and compared with less common solvents such as ethyl acetate, chloroform, or a mixture of chloroform with isopropanol. Almost independent of the pH of the aqueous phase extraction yields in LLE were generally low (<23%) with TBME giving the worst recovery (<5%) of all extraction solvents tested in this investigation. SPE using Oasis HLB resulted in the highest recovery (96%) for extraction after optimization of the procedure. According to literature Lichrolut RP-18 also gave recoveries of 72-96% [34] . Thus, it is suggested to perform either dilute-and-inject or SPE for sample preparation rather than LLE. Utilizing MS/MS (spectrum in Figure 6 upper), the comparison with the product ion spectrum of 14-desoxy-ecdysterone as reported in Figure 5 revealed high similarities, thus, considering high probability of conformance. Additionally, the GC-QTOF-MS analysis showed a signal matching 14-desoxy-ecdysterone spectrum and retention time. Fragments look very similar to those reported for 2-desoxy-ecdysterone by Tsitsimpikou et al. [33] , however showing different relative abundances. As already commented by Lafont and Dinan [10] mass spectrometry is not capable of providing data suitable for unambiguous assignment of the exact isomer. Even worse, also product ion spectra of ecdysteroids after ESI are dominated by losses of water that are not suitable for a discrimination of the position of desoxygenation at the sterane moiety.
Detection of ecdysterone metabolites in urine
Similarly the EI-spectra reported by Tsitsimpikou et al. [33] are dominated by cleavage of the sterane moiety from the side chain and subsequent losses of TMSOH, that, again, do not provide suitable discrimination of the positional isomers. Thus, in the future synthesis of additional, authentic reference material is needed for proper isomer identification of isolated metabolites, by comparison of the retention times. As already discovered for ecdysterone, no relevant phase-II metabolite was detectable by accurate mass in the non-hydrolyzed samples and no increase in abundance was detected after enzymatic hydrolysis. This is in line with the findings in mice reported by Lafont et al. [31] . the bacterial composition may highly influence metabolite excretion. An evaluation of post administration urines of different volunteers is thus highly desired.
Excretion profiles
Following a single oral dose of 51.5 mg of ecdysterone the parent compound was detectable by LC-QTOF-MS for more than two days using dilute-and-inject. The maximum concentration was observed in the 2.0-3.5 h urine. The desoxy metabolite M3 shows a smaller detection window compared to the parent compound. The maximum concentration was detected in the 7.25-9.0 h urine, and latest detection was achieved in the 25.2-29 h urine. The excretion profiles of both metabolites are displayed in Figure 8 . A biphasic excretion of the two desoxypoststerone isomers has been also observed, however needs further investigation.
Conclusion
An administration of ecdysterone results in an excretion of the parent compound in the urine.
Targeting the parent compound is ideally performed by LC-HRMS or LC-MS/MS by dilute-andinject. Alternatively, GC-MS analysis is possible after TMS derivatization. If extraction is required or desired, SPE was found by far superior to LLE. Enzymatic hydrolysis did not provide advantages over the analysis of the unconjugated fraction only. Ecdysterone and its desoxy metabolite may be easily integrated in current initial testing procedures (ITP) for monitoring the prevalence in elite sports.
Due to the potential generation of metabolites by gut bacteria that may cause significant variations in the metabolic profile, an integration of further isomers and analogues may also be appropriate. Furthermore ecdysterone is often administered from plant extracts such as spinach or suma root. Thus, further phytosteroids (e.g. ecdysone, ponasterone, and others) may be ingested aside. These steroids as well as their metabolites may be found in excretion urines as well. 
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